Hologic announced contract with BARDA to support IVD approval of COVID assays
On Nov. 2, 2022, Hologic announced that it had been awarded a $19 million contract from the Biomedical…
Pfizer announced positive top-line data of phase 3 global trial for bivalent RSV vaccine candidate
On Nov. 1, 2022, Pfizer announced positive top-line data from the Phase 3 clinical trial (NCT04424316) MATISSE (MATernal…
Biotechnology | COVID-19 | Diagnostics | Influenza | Life Science History | Life Science News | Medical Device
BD launched combination test for COVID-19, Influenza A/B and Respiratory Syncytial Virus
On Jun. 30, 2022, BD (Becton, Dickinson) announced that the BD MAX Respiratory Viral Panel (RVP), a new…
Labcorp received EUA for first non-prescription at-home collection kit for combined COVID-19, Fflu and RSV detection
On May 18, 2022, LabCorp announced the receipt of Emergency Use Authorization (EUA) from the U.S. Food and…
Cepheid received Health Canada license for Xpert Xpress CoV-2/Flu/RSV plus
On Jan, 25, 2022, Cepheid announced that Health Canada had issued Cepheid a medical device license for Xpert…
Cepheid received CE Mark for Xpert Xpress CoV-2/Flu/RSV plus
On Oct. 14, 2021, Cepheid announced it had received the CE mark for Xpert Xpress CoV-2/Flu/RSV plus, a…
PerkinElmer received FDA Emergency Use Authorization for respiratory SARS-CoV-2 panel
On Oct. 7, 2021, PerkinElmer announced that the U.S. Food and Drug Administration (FDA) had issued Emergency Use…
Cepheid received Emergency Use Authorization For SARS-CoV-2, Flu A, Flu B and RSV combination test
On Sept. 29, 2021, Cepheid announced it had received Emergency Use Authorization from the U.S. Food & Drug…
Moderna received FDA Fast Track Designation for Respiratory Syncytial Virus vaccine
On Aug. 3, 2021, Moderna announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track…
Luminex submitted joint SARS-CoV-2 and Flu/RSV respiratory panel to FDA for Emergency Use Authorization
On Mar. 10, 2021, Luminex announced that it had submitted an Emergency Use Authorization application to the U.S….
Abbott’s received FDA EUA for laboratory PCR assay that detects and differentiates SARS-CoV-2, Flu A, Flu B and RSV
On Mar. 5, 2021, Abbott announced FDA Emergency Use Authorization (EUA) for the company’s Alinityï¾™ m Resp-4-Plex molecular…
Altasciences announced phase I research for COVID-19 pneumonia treatment
On Mar. 3, 2021, Altasciences announced support for ReAlta Life Sciences’ Phase I trial to evaluate RLS-0071 for…
Luminex received BARDA funding to support development and validation of test combining SARS-CoV-2 and Flu/RSV respiratory pane
On Feb. 19, 2021, Luminex announced that it had received $11.3 million in funding from the Biomedical Advanced…
Cepheid received Health Canada license for SARS-CoV-2, Flu A, Flu B and RSV combination test
On Jan. 14, 2021, Cepheid that Health Canada announced that it had issued Cepheid a medical device license…
Biotechnology | COVID-19 | HIV | Influenza | Life Science News | Vaccine
Moderna announced three new development programs in infectious disease vaccines
On Jan. 11, 2021, Moderna announced that it was expanding its pipeline of innovative vaccines with three new…
CerTest Biotec and BD announced CE Mark for combination COVID-19, Influenza, RSV test
On Oct. 21, 2020, CerTest Biotec, along with BD (Becton, Dickinson), announced that the VIASURE SARS-CoV-2 (N1 +…
DiaSorin Molecular received FDA clearance for the Simplexaï¾™ flu A/B & RSV direct gen II assay Simplexaï¾™ Flu A/B & RSV Direct Gen II Assay
On Sept. 8, 2020, DiaSorin Molecular announced that it had received FDA Clearance for its Simplexaï¾™ Flu A/B…
LabCorp launched first combined test for Covid-19, flu and RSV in time for flu season
On Sept. 8, 2020, LabCorpï¾® announced the launch of the first testing method to simultaneously detect COVID-19, influenza…
Pfizer announced start of four phase 3 clinical trials for investigational vaccines
On Jun. 22, 2020, Pfizer announced the initiation of four phase 3 clinical trials within its current pipeline…
Mesa Biotech received funding from HHS for development of a 30 minute molecular point-of-care SARS-CoV-2 test
On Mar. 19, 2020, Mesa Biotech announced it had been awarded a $561,000 contract from the U.S. Department…